Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs are becoming increasingly popular in Western Africa as the region experiences a rise in respiratory diseases.
Customer preferences: Customers in Western Africa are increasingly looking for affordable and effective treatments for respiratory diseases. Bronchodilator drugs are preferred due to their quick relief of symptoms such as shortness of breath, wheezing, and chest tightness. Customers also prefer drugs that are easy to use and have minimal side effects.
Trends in the market: The Bronchodilator Drugs market in Western Africa is expected to grow due to the rising prevalence of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The market is also driven by the increasing awareness of the benefits of early diagnosis and treatment of respiratory diseases. The demand for combination bronchodilator drugs is also increasing as they provide better symptom relief and are more convenient for patients.
Local special circumstances: The region faces unique challenges such as poor air quality, high levels of pollution, and a lack of access to healthcare facilities. These factors contribute to the high prevalence of respiratory diseases in the region. Additionally, the low-income population in Western Africa is unable to afford expensive treatments, making affordable bronchodilator drugs a more attractive option.
Underlying macroeconomic factors: The economic growth in Western Africa has led to an increase in the number of people with access to healthcare services. This, coupled with the rising prevalence of respiratory diseases, has led to an increase in demand for bronchodilator drugs. The region also has a growing middle class that is more aware of the importance of healthcare and is willing to spend on treatments. However, the lack of regulatory frameworks and a weak healthcare infrastructure continue to pose a challenge to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
